2024-10-25 - Analysis Report
## Gilead Sciences Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences Inc. is a biopharmaceutical company that develops, manufactures, and markets drugs for various medical conditions, including HIV, hepatitis B and C, cancer, and inflammatory diseases.

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (GILD):** -8.61%
* **Cumulative Return (VOO):** 135.48%
* **Performance Difference:** -144.09% 
* **Relative Performance:** 7.18% (This means GILD's performance is in the 7.18th percentile of its historical performance compared to VOO, implying it has significantly underperformed the benchmark index.)

**2. Recent Price Movements:**

* **Closing Price:** $88.78 
* **5-day Moving Average:** $87.09
* **20-day Moving Average:** $85.59
* **60-day Moving Average:** $80.82 

**3. Technical Indicators:**

* **RSI:** 73.2 (This indicates the stock is currently in overbought territory, suggesting potential for a pullback.)
* **PPO:** 0.02 (The PPO is positive, suggesting a potential bullish trend.)
* **Delta_Previous_Relative_Divergence:** 2.15 (+) (This indicates a short-term uptrend.)
* **Expected Return:** 0.0% (This implies that GILD is not expected to outperform the S&P 500 over the long term based on current market conditions.) 

**4. Recent Earnings and Outlook:**

| Date      | EPS    | Revenue        |
|-----------|--------|----------------|
| 2024-08-08 | 1.29  | 6.95 B$      |
| 2024-05-08 | -3.34 | 6.69 B$      |
| 2023-11-07 | 1.75  | 7.05 B$      |
| 2023-08-04 | 0.84  | 6.60 B$      |
| 2024-08-08 | 0.84  | 6.60 B$      |

* **Most Recent Earnings (2024-08-08):** The recent earnings were slightly better than analyst expectations. 
* **Outlook:** The outlook for Gilead's future earnings is uncertain due to ongoing competition in the market and potential headwinds from the broader pharmaceutical industry.

**5. News and Recent Developments:**

* **Recent Earnings News:** The recent earnings release (Aug 8th, 2024) was covered by various financial news outlets, including Shacknews, reporting on the company's strong revenue and earnings performance.
* **Analyst Opinions and Performance Highlights:** FINBOLD recently reported that analysts are cautiously optimistic about GILD's prospects due to the company's diversified portfolio and its focus on key therapeutic areas.

**6. Overall Analysis:**

* Gilead Sciences Inc. (GILD) has significantly underperformed the S&P 500 (VOO) in recent years.
* The stock is currently in overbought territory, and its technical indicators suggest potential for a pullback.
* The recent earnings release was positive, but the company's future prospects are uncertain due to competitive pressures and industry headwinds. 
* The company has a diverse portfolio and a focus on key therapeutic areas.

**7. Conclusion:**

While GILD's recent earnings were positive, the stock's overall performance has lagged behind the market. Its current overbought condition and the uncertain outlook for the broader pharmaceutical industry create uncertainty for future performance. Investors considering GILD should carefully assess their risk tolerance and consider the potential for a short-term pullback before investing. 
